Last reviewed · How we verify
Flublok® Quadrivalent Influenza Virus Vaccine
Flublok® Quadrivalent Influenza Virus Vaccine is a Influenza vaccine Biologic drug developed by Protein Sciences Corporation. It is currently in Phase 3 development for Active immunization against influenza disease caused by influenza A and B virus strains in adults 18 years of age and older. Also known as: Recombinant Influenza Vaccine (RIV4), Flublok Influenza Vaccine, rHA, rHA0.
Flublok stimulates the immune system to produce antibodies against four strains of influenza virus by presenting recombinant hemagglutinin antigens.
Flublok stimulates the immune system to produce antibodies against four strains of influenza virus by presenting recombinant hemagglutinin antigens. Used for Active immunization against influenza disease caused by influenza A and B virus strains in adults 18 years of age and older.
At a glance
| Generic name | Flublok® Quadrivalent Influenza Virus Vaccine |
|---|---|
| Also known as | Recombinant Influenza Vaccine (RIV4), Flublok Influenza Vaccine, rHA, rHA0, Recombinant Hemagglutinin |
| Sponsor | Protein Sciences Corporation |
| Drug class | Influenza vaccine |
| Target | Influenza hemagglutinin (HA) antigen |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Flublok Quadrivalent is a recombinant protein-based influenza vaccine that uses insect cell technology to produce hemagglutinin antigens from four influenza virus strains (two A strains and two B strains). These antigens are presented to the immune system to elicit humoral and cellular immune responses, generating protective antibodies and memory immunity against the targeted influenza strains.
Approved indications
- Active immunization against influenza disease caused by influenza A and B virus strains in adults 18 years of age and older
Common side effects
- Injection site pain
- Injection site erythema
- Injection site swelling
- Myalgia
- Headache
- Fatigue
Key clinical trials
- Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above (PHASE1)
- Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years (PHASE3)
- A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above (PHASE1, PHASE2)
- Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older (PHASE1, PHASE2)
- Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older (PHASE1, PHASE2)
- Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older (PHASE1, PHASE2)
- A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults (PHASE4)
- Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flublok® Quadrivalent Influenza Virus Vaccine CI brief — competitive landscape report
- Flublok® Quadrivalent Influenza Virus Vaccine updates RSS · CI watch RSS
- Protein Sciences Corporation portfolio CI
Frequently asked questions about Flublok® Quadrivalent Influenza Virus Vaccine
What is Flublok® Quadrivalent Influenza Virus Vaccine?
How does Flublok® Quadrivalent Influenza Virus Vaccine work?
What is Flublok® Quadrivalent Influenza Virus Vaccine used for?
Who makes Flublok® Quadrivalent Influenza Virus Vaccine?
Is Flublok® Quadrivalent Influenza Virus Vaccine also known as anything else?
What drug class is Flublok® Quadrivalent Influenza Virus Vaccine in?
What development phase is Flublok® Quadrivalent Influenza Virus Vaccine in?
What are the side effects of Flublok® Quadrivalent Influenza Virus Vaccine?
What does Flublok® Quadrivalent Influenza Virus Vaccine target?
Related
- Drug class: All Influenza vaccine drugs
- Target: All drugs targeting Influenza hemagglutinin (HA) antigen
- Manufacturer: Protein Sciences Corporation — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Active immunization against influenza disease caused by influenza A and B virus strains in adults 18 years of age and older
- Also known as: Recombinant Influenza Vaccine (RIV4), Flublok Influenza Vaccine, rHA, rHA0, Recombinant Hemagglutinin
- Compare: Flublok® Quadrivalent Influenza Virus Vaccine vs similar drugs
- Pricing: Flublok® Quadrivalent Influenza Virus Vaccine cost, discount & access